​

Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALNY Stock Forecast

Alnylam Pharmaceuticals (ALNY) stock forecast, based on 52 Wall Street analysts, predicts a 12-month average price target of $438.50, with a high of $485.00 and a low of $400.00. This represents a 61.35% increase from the last price of $271.77.

$100 $180 $260 $340 $420 $500 High: $485 Avg: $438.5 Low: $400 Last Closed Price: $271.77

ALNY Stock Rating

Alnylam Pharmaceuticals stock's rating consensus is Buy, based on 52 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 39 Buy (75.00%), 12 Hold (23.08%), 1 Sell (1.92%), and 0 Strong Sell (0.00%).

Buy
Total 52 1 12 39 Strong Sell Sell Hold Buy Strong Buy

ALNY Price Target Upside V Benchmarks

TypeNameUpside
StockAlnylam Pharmaceuticals61.35%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts5733
Avg Price Target$446.60$435.71$463.70
Last Closing Price$271.77$271.77$271.77
Upside/Downside64.33%60.32%70.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 267148--29
Jun, 267158--30
May, 266148--28
Apr, 266148--28
Mar, 266157--28
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jul 13, 2026H.C. Wainwright$485.00$288.0868.36%78.46%
Jul 13, 2026Truist Financial$410.00$298.7637.23%50.86%
Jul 10, 2026Morgan Stanley$400.00$307.4230.12%47.18%
Jul 09, 2026Raymond James$468.00$322.6445.05%72.20%
Jun 29, 2026H.C. Wainwright$470.00$291.3761.31%72.94%
May 01, 2026Morgan Stanley$370.00$301.4522.74%36.14%
May 01, 2026Bernstein$447.00$302.8547.60%64.48%
Feb 17, 2026Canaccord Genuity$429.00$314.4036.45%57.85%
Feb 13, 2026Morgan Stanley$360.00$313.7514.74%32.46%
Feb 13, 2026Bernstein$451.00$312.4344.35%65.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 09, 2026Raymond JamesOutperformOutperformhold
Jun 29, 2026H.C. WainwrightBuyBuyhold
Jun 05, 2026H.C. WainwrightBuyBuyhold
May 18, 2026CitigroupBuyBuyinitialise
Feb 12, 2026Bank of America SecuritiesBuyBuyhold
Jan 12, 2026NeedhamBuyBuyhold
Jan 12, 2026Bank of America SecuritiesBuyBuyhold
Jan 12, 2026Raymond JamesOutperformOutperformhold
Nov 04, 2025H.C. WainwrightBuyBuyhold
Oct 31, 2025BarclaysOverweightOverweighthold

Financial Forecast

EPS Forecast

$-15 $-8 $-1 $6 $13 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.20$-9.30$-3.52$-2.18$2.39---
Avg Forecast$-6.44$-8.95$-3.48$-2.10$-1.04$2.91$6.52$12.25
High Forecast$-5.41$-7.68$-2.38$0.75$4.40$9.93$19.04$15.89
Low Forecast$-7.61$-10.93$-4.20$-3.77$-11.85$-1.93$2.05$10.34
Surprise %11.80%3.91%1.15%3.81%-329.81%---

Revenue Forecast

$500M $2B $3B $5B $6B $8B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$844.29M$1.04B$1.83B$2.25B$3.71B---
Avg Forecast$820.81M$1.01B$1.83B$2.24B$2.65B$3.54B$4.54B$5.85B
High Forecast$934.80M$1.19B$1.88B$2.27B$3.06B$3.55B$4.61B$7.19B
Low Forecast$719.95M$902.76M$1.77B$2.20B$2.40B$3.53B$4.47B$5.15B
Surprise %2.86%2.38%0.12%0.35%40.28%---

Net Income Forecast

$-2B $-700M $100M $900M $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-852.82M$-1.13B$-440.24M$-278.16M$313.75M---
Avg Forecast$-723.17M$-770.44M$-440.24M$-332.26M$-196.87M$330.06M$942.06M$1.53B
High Forecast$-578.53M$-616.35M$-352.19M$94.21M$549.62M$1.24B$2.38B$1.99B
Low Forecast$-867.80M$-924.53M$-528.29M$-471.06M$-1.48B$-240.59M$255.91M$1.29B
Surprise %17.93%46.82%--16.28%-259.37%---

ALNY Forecast FAQ

Is Alnylam Pharmaceuticals stock a buy?

Alnylam Pharmaceuticals stock has a consensus rating of Buy, based on 52 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 39 Buy, 12 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Alnylam Pharmaceuticals is a favorable investment for most analysts.

What is Alnylam Pharmaceuticals's price target?

Alnylam Pharmaceuticals's price target, set by 52 Wall Street analysts, averages $438.5 over the next 12 months. The price target range spans from $400 at the low end to $485 at the high end, suggesting a potential 61.35% change from the previous closing price of $271.77.

How does Alnylam Pharmaceuticals stock forecast compare to its benchmarks?

Alnylam Pharmaceuticals's stock forecast shows a 61.35% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Alnylam Pharmaceuticals over the past three months?

  • July 2026: 24.14% Strong Buy, 48.28% Buy, 27.59% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 23.33% Strong Buy, 50.00% Buy, 26.67% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 21.43% Strong Buy, 50.00% Buy, 28.57% Hold, 0% Sell, 0% Strong Sell.

What is Alnylam Pharmaceuticals’s EPS forecast?

Alnylam Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $2.91, marking a 21.76% increase from the reported $2.39 in 2025. Estimates for the following years are $6.52 in 2027, and $12.25 in 2028.

What is Alnylam Pharmaceuticals’s revenue forecast?

Alnylam Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $3.54B, reflecting a -4.60% decrease from the reported $3.71B in 2025. The forecast for 2027 is $4.54B, and $5.85B for 2028.

What is Alnylam Pharmaceuticals’s net income forecast?

Alnylam Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $330.06M, representing an 5.20% increase from the reported $313.75M in 2025. Projections indicate $942.06M in 2027, and $1.53B in 2028.